INCY240920C67500
- 0.46
- -0.24-34.29%
Incyte Newsroom
Incyte Downgraded at Truist on Jakafi Patent Cliff
Update: Truist Securities Downgrades Incyte to Hold From Buy, Cuts Price Target to $74 From $83
Truist Financial Downgrades Incyte(INCY.US) to Hold Rating, Announces Target Price $74
Incyte Analyst Ratings
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $64 to $92
Incyte Is Maintained at Buy by Guggenheim
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $64 to $92
Incyte Analyst Ratings
B of A Securities Maintains Neutral on Incyte, Raises Price Target to $68
TD Cowen Sticks to Its Buy Rating for Incyte (INCY)
Incyte's Promising Clinical Data Balanced With Regulatory Uncertainty: A 'Hold' Recommendation
BofA Securities Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $66
Incyte's CDK2i: A Cautiously Optimistic Neutral Rating Amidst Early Clinical Data and Safety Concerns
Incyte Analyst Ratings
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $67
RBC Capital Sticks to Their Hold Rating for Incyte (INCY)
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cochlear Limited (OtherCHEOF)
Incyte's Niktimvo Faces Market Challenges Despite FDA Approval: Analyst Upholds Hold Rating